Published in J Liposome Res on February 26, 2003
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Nanoparticles and the immune system. Endocrinology (2009) 1.79
Challenges in development of nanoparticle-based therapeutics. AAPS J (2012) 1.28
Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res (2010) 1.12
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
Nanoparticles for imaging, sensing, and therapeutic intervention. ACS Nano (2014) 0.94
Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J Neurooncol (2009) 0.90
Surface engineering of liposomes for stealth behavior. Pharmaceutics (2013) 0.90
Complement activation and cell uptake responses toward polymer-functionalized protein nanocapsules. Biomacromolecules (2012) 0.89
Nanoparticle Uptake: The Phagocyte Problem. Nano Today (2015) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) (2011) 0.83
Biological evaluation of liposome-encapsulated hemoglobin surface-modified with a novel PEGylated nonphospholipid amphiphile. Artif Organs (2014) 0.80
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) (2012) 0.77
Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy. Front Immunol (2017) 0.75
Anaphylaxis to pegylated liposomal Doxorubicin: a case report. West Indian Med J (2014) 0.75
Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. Front Immunol (2017) 0.75
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control (2001) 5.38
Fluidity parameters of lipid regions determined by fluorescence polarization. Biochim Biophys Acta (1978) 4.61
Sedimentation of generalized systems of interacting particles. I. Solution of systems of complete Lamm equations. Biopolymers (1975) 4.49
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet (2007) 4.45
A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry (1977) 4.21
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res (1994) 3.30
Dynamics of the hydrocarbon layer in liposomes of lecithin and sphingomyelin containing dicetylphosphate. J Biol Chem (1974) 3.28
Hospital peer review and the National Practitioner Data Bank: clinical privileges action reports. JAMA (1999) 3.24
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
Social network ties and mortality among the elderly in the Alameda County Study. Am J Epidemiol (1987) 2.69
Fluorescence depolarization studies of phase transitions and fluidity in phospholipid bilayers. 2 Two-component phosphatidylcholine liposomes. Biochemistry (1976) 2.63
A new surgical procedure for the treatment of gastroesophageal reflux and hiatal hernia. Surg Gynecol Obstet (1979) 2.57
Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol (2009) 2.52
Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med (1990) 2.33
The ethics objective structured clinical examination. J Gen Intern Med (1993) 2.32
Fluorescence depolarization studies of phase transitions and fluidity in phospholipid bilayers. 1. Single component phosphatidylcholine liposomes. Biochemistry (1976) 2.27
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Fungal flora of the normal human small and large intestine. N Engl J Med (1969) 2.25
A calorimetric and fluorescent probe study of the gel-liquid crystalline phase transition in small, single-lamellar dipalmitoylphosphatidylcholine vesicles. Biochemistry (1976) 2.21
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Sphingomyelins in bilayers and biological membranes. Biochim Biophys Acta (1980) 2.07
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant (2002) 2.06
Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology (2008) 2.04
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Effect of a tumour promoter on myogenesis. Nature (1977) 1.98
Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med (2000) 1.98
Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest (2000) 1.94
Graduates of foreign medical schools: demographic and personal predictors of success on an OSCE-format internship programme entrance examination. Res Med Educ (1988) 1.86
Interaction of Sindbis virus with liposomal model membranes. J Virol (1975) 1.85
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84
Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A (1978) 1.82
Tumour-targeted nanomedicines: principles and practice. Br J Cancer (2008) 1.81
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res (2001) 1.79
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol (1995) 1.77
Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience (2008) 1.76
Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry (1969) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Reliability and construct validity of a structured technical skills assessment form. Am J Surg (1994) 1.72
Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets (2009) 1.70
Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med (1977) 1.70
Identification of a regulatory region that mediates glucose-dependent induction of the Saccharomyces cerevisiae enolase gene ENO2. Mol Cell Biol (1986) 1.69
Sedimentation of generalized systems of interacting particles. II. Active enzyme centrifugation--theory and extensions of its validity range. Biopolymers (1975) 1.64
Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand (2006) 1.63
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Thermal behavior of synthetic sphingomyelin-cholesterol dispersions. Biochemistry (1979) 1.62
Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev (2001) 1.62
Airborne endotoxin associated with industrial-scale production of protein products in gram-negative bacteria. Am Ind Hyg Assoc J (1988) 1.61
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol (2001) 1.59
Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother (2000) 1.57
Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res (1971) 1.57
Benefits of Ophdiat, a telemedical network to screen for diabetic retinopathy: a retrospective study in five reference hospital centres. Diabetes Metab (2009) 1.56
Laparascopic excision of pelvic kidney with single vaginal ectopic ureter. J Pediatr Surg (1997) 1.56
Percolation in directed scale-free networks. Phys Rev E Stat Nonlin Soft Matter Phys (2002) 1.56
Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther (2001) 1.55
Skin immunization made possible by cholera toxin. Nature (1998) 1.55
Enveloped viruses as model membrane systems: microviscosity of vesicular stomatitis virus and host cell membranes. Biochemistry (1976) 1.54
Structural family versus psychodynamic child therapy for problematic Hispanic boys. J Consult Clin Psychol (1989) 1.53
Inhaled antibiotics in cystic fibrosis. Lancet (1983) 1.53
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol (1989) 1.53
Comparison of the 15q deletions in Prader-Willi and Angelman syndromes: specific regions, extent of deletions, parental origin, and clinical consequences. Am J Med Genet (1990) 1.53
States of aggregation and phase transformations in mixtures of phosphatidylcholine and octyl glucoside. Biochemistry (1990) 1.51
Is the period of rapidly declining adult mortality in the United States coming to an end? Am J Public Health (1983) 1.50
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
The type 2 family: a setting for development and treatment of adolescent type 2 diabetes mellitus. Arch Pediatr Adolesc Med (1999) 1.49
Ventricular laceration and cardiac tamponade during laparoscopic Nissen fundoplication. Surg Laparosc Endosc (1996) 1.48
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun (2000) 1.48
Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med (1978) 1.48
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol (1991) 1.47
Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol (2001) 1.46
Guidelines for estimating the real cost of an objective structured clinical examination. Acad Med (1993) 1.45
Vaccination against meningococcus C. vaccinal coverage in the French target population. Med Mal Infect (2013) 1.45
Treatment of breast cancer with medroxyprogesterone acetate. Ann Intern Med (1968) 1.45
A calorimetric study of the thermotropic behavior of aqueous dispersions of natural and synthetic sphingomyelins. Biochemistry (1976) 1.45
Increasing trends in the use of breast-conserving surgery in California. Am J Public Health (2000) 1.44
Normal viral and bacterial flora of the human small and large intestine. N Engl J Med (1966) 1.44
Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis (2014) 1.44
Nomenclature for synthetic gene delivery systems. Hum Gene Ther (1997) 1.44
An in vitro assay based on surface plasmon resonance to predict the in vivo circulation kinetics of liposomes. J Control Release (2011) 1.43
Sexual agglutinins from the Chlamydomonas flagellar membrane. Partial purification and characterization. J Biol Chem (1982) 1.42
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol (1999) 1.41
Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol (1998) 1.41
An objective structured clinical examination for the licentiate of the Medical Council of Canada: from research to reality. Acad Med (1993) 1.41
Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst (1996) 1.40
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
[Meningeal myelomatosis. Presentation of a case]. Sangre (Barc) (1992) 1.38
The hot clot sign. A new finding in deep venous thrombosis on bone scintigraphy. Clin Nucl Med (1990) 1.38
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A (1992) 1.37
[Treatment of Streptococcus pneumoiae meningitis in infants]. Arch Pediatr (1994) 1.37
In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis. Antimicrob Agents Chemother (1994) 1.37